Edwards Lifesciences announced on August 19, 2025, that it has executed an accelerated share repurchase (ASR) agreement to repurchase $500 million of its common stock. This transaction is part of the company's ongoing capital allocation strategy.
With this latest ASR, Edwards Lifesciences has repurchased more than $800 million of shares in 2025. The company will receive an initial delivery of approximately 5 million shares, with the remainder to be delivered at the maturity of the ASR, based on the volume-weighted average share price.
The share repurchase is being funded with existing cash, demonstrating the company's strong financial position. Following this transaction, Edwards has approximately $600 million remaining under its current share repurchase authorization, signaling potential for further shareholder returns.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.